Hunter TM, Boytsov NN, Zhang X, Schroeder K, Michaud K, Araujo AB. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37(9):1551–7.

PubMed  Article  Google Scholar 

Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheumatol. 2008;58(1):15–25.

Article  Google Scholar 

Kim SC, Yelin E, Tonner C, Solomon DH. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983–2009. Arthritis Care Res (Hobok). 2013;65(9):1529–33.

CAS  Article  Google Scholar 

Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm. 2017;23(8):809–14.

PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, et al. 2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–39.

Article  Google Scholar 

Uson J, Rodriguez-García SC, Castellanos-Moreira R, et al. EULAR recommendations for intra-articular therapies. Ann Rheum Dis. 2021;2021:annrheumdis-2021-220266.

Wei W, Knapp K, Wang L, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. Adv Ther. 2017;34(8):1936–52.

PubMed  PubMed Central  Article  Google Scholar 

Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259–65.

PubMed  Article  Google Scholar 

Harnett J, Wiederkehr D, Gerber R, Gruben D, Koenig A, Bourret J. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. J Med Econ. 2016;19(2):91–102.

PubMed  Article  Google Scholar 

Shahabi A, Shafrin J, Zhao L, et al. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients. J Med Econ. 2019;22(4):350–8.

PubMed  Article  Google Scholar 

Kim G, Barner JC, Rascati K, Richards K. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2015;21(5):401–7.

PubMed  Google Scholar 

Oladapo A, Barner JC, Lawson KA, et al. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis. J Manag Care Spec Pharm. 2014;20(7):657–67.

PubMed  Google Scholar 

Rashid N, Lin AT, Aranda G Jr, et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. J Med Econ. 2016;19(6):568–75.

PubMed  Article  Google Scholar 

Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S205-207.

CAS  PubMed  Google Scholar 

van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S195-200.

PubMed  Google Scholar 

Kremer JM. The Corrona US registry of rheumatic and autoimmune diseases. Clin Exp Rheumatol. 2016;34(5 Suppl 101):S96-s99.

PubMed  Google Scholar 

Hetland ML, Lindegaard HM, Hansen A, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. Ann Rheum Dis. 2008;67(7):1023–6.

CAS  PubMed  Article  Google Scholar 

Pappas DA, Litman HJ, Lesperance T, et al. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. Rheumatol Int. 2021;41(2):381–90.

CAS  PubMed  Article  Google Scholar 

Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354–60.

CAS  PubMed  Article  Google Scholar 

Bergman M, Zhou L, Patel P, Sawant R, Clewell J, Tundia N. Healthcare costs of not achieving remission in patients with rheumatoid arthritis in the United States: a retrospective cohort study. Adv Ther. 2021;38(5):2558–70.

PubMed  PubMed Central  Article  Google Scholar 

Kim SY, Servi A, Polinski JM, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011;13(1):R32.

PubMed  PubMed Central  Article  Google Scholar 

Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.

PubMed  PubMed Central  Article  Google Scholar 

Sun JW, Rogers JR, Her Q, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046–51.

PubMed  Article  Google Scholar 

Kim DH, Glynn RJ, Avorn J, et al. Validation of a claims-based frailty index against physical performance and adverse health outcomes in the health and retirement study. J Gerontol A Biol Sci Med Sci. 2019;74(8):1271–6.

PubMed  Article  Google Scholar 

Zhang Y, Li R, Tsai C-L. Regularization parameter selections via generalized information criterion. J Am Stat Assoc. 2010;105(489):312–23.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chand S. On tuning parameter selection of lasso-type methods—a monte carlo study. In: Paper presented at: Proceedings of 2012 9th International Bhurban Conference on Applied Sciences & Technology (IBCAST); 2012.

Desai RJ, Wang SV, Vaduganathan M, Evers T, Schneeweiss S. Comparison of machine learning methods with traditional models for use of administrative claims with electronic medical records to predict heart failure outcomes. JAMA Netw Open. 2020;3(1):e1918962–e1918962.

PubMed  PubMed Central  Article  Google Scholar 

Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.

CAS  PubMed  Article  Google Scholar 

Dore RK, Antonova J, Burudpakdee C, Wang X, Ozbay B, Genovese MC. SAT0133 treatment patterns, persistence, and durability in rheumatoid arthritis patients with inadequate response to biologic disease-modifying anti-rheumatic drugs (BDMARDS). Ann Rheum Dis. 2019;78(Suppl 2):1135–6.

Google Scholar 

Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther. 2017;34(11):2422–35.

PubMed  PubMed Central  Article  Google Scholar 

Meijboom RW, Gardarsdottir H, Becker ML, et al. Switching TNFα inhibitors: patterns and determinants. Pharmacol Res Perspect. 2021;9(4): e00843.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Li K-J, Chang C-L, Hsin C-Y, Tang C-H. Switching and discontinuation pattern of biologic disease-modifying antirheumatic drugs and tofacitinib for patients with rheumatoid arthritis in Taiwan. Front Pharmacol. 2021;2021:12.

Google Scholar 

Fletcher A, Lassere M, March L, et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology. 2022;2022:5.

Google Scholar 

Saevarsdottir S, Wedrén S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011;63(1):26–36.

CAS  PubMed  Article  Google Scholar 

Schäfer M, Meißner Y, Kekow J, et al. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology. 2019;59(8):1916–26.

PubMed Central  Article  CAS  Google Scholar 

Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. Rheumatology. 2016;55(12):2191–9.

PubMed  Article  CAS  Google Scholar 

Micheroli R, Hebeisen M, Wildi LM, et al. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2017;19(1):164–164.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Suh YS, Cheon YH, Kim HO, et al. Medication nonadherence in Korean patients with rheumatoid arthritis: the importance of belief about medication and illness perception. Korean J Intern Med. 2018;33(1):203–10.

PubMed  Article  Google Scholar 

Wabe N, Lee A, Wechalekar M, McWilliams L, Proudman S, Wiese M. Factors associated with medication adherence in a longitudinal study of rheumatoid arthritis patients. Int J Clin Pract. 2019;73(7): e13375.

PubMed  Article  CAS  Google Scholar 

Rodrigues JR, Faria DS, Neves JS, et al. Positive affect as a predictor of adherence in patients with Rheumatoid Arthritis. Acta Reumatol Portuguesa. 2019;44(2):132–7.

Google Scholar 

Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43(1):18–28.

PubMed  Article  Google Scholar 

Morgan C, McBeth J, Cordingley L, et al. The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatol (Oxf). 2015;54(10):1780–91.

CAS  Article  Google Scholar 

Kumar K, Raza K, Nightingale P, et al. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study. BMC Musculoskelet Disord. 2015;16:396.

PubMed  PubMed Central  Article  CAS